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The Neuroendocrine Peptide Catestatin Is a
Cutaneous Antimicrobial and Induced in the Skin
after Injury
Katherine A. Radek1,2,6, Belen Lopez-Garcia1,2,6,7, Melanie Hupe3,4, Ingrid R. Niesman1, Peter M. Elias3,4,
Laurent Taupenot1,2, Sushil K. Mahata1,2, Daniel T. O’Connor1,2,5 and Richard L. Gallo1,2
Epithelia establish a microbial barrier against infection through the production of antimicrobial peptides
(AMPs). In this study, we investigated whether catestatin (Cst), a peptide derived from the neuroendocrine
protein chromogranin A (CHGA), is a functional AMP and is present in the epidermis. We show that Cst is
antimicrobial against relevant skin microbes, including Gram-positive and Gram-negative bacteria, yeast, and
fungi. The antimicrobial mechanism of Cst was found to be similar to other AMPs, as it was dependent on
bacterial charge and growth conditions, and induced membrane disruption. The potential relevance of Cst
against skin pathogens was supported by the observation that CHGA was expressed in keratinocytes. In human
skin, CHGA was found to be proteolytically processed into the antimicrobial fragment Cst, thus enabling its
AMP function. Furthermore, Cst expression in murine skin increased in response to injury and infection,
providing potential for increased protection against infection. These data demonstrate that a neuroendocrine
peptide has antimicrobial function against a wide assortment of skin pathogens and is upregulated upon injury,
thus demonstrating a direct link between the neuroendocrine and cutaneous immune systems.
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INTRODUCTION
Epithelia such as the skin impede the penetration of microbes
by its structural integrity, pH, and biochemical constituents
such as lipids, peptides, and proteins. Antimicrobial peptides
(AMPs) are major components of this defense system and
include multiple gene families encoding these ‘‘natural
antibiotics.’’ These AMPs are essential for function at the
boundary with the external environment as a rapid first line of
defense against invasion by pathogens including bacteria,
viruses, and fungi (Stolzenberg et al., 1997; Bals et al., 1998;
Nizet et al., 2001; Bardan et al., 2004; Murakami et al., 2004;
Schauber et al., 2007). Some AMPs, for instance, HBD-2
(human b-defensin 2) (Harder et al., 1997), HBD-3 (Harder
et al., 2001), and cathelicidin (Dorschner et al., 2001;
Schauber et al., 2007), are expressed at low levels
constitutively, but are inducible following infection or injury.
The mechanism of action for such cationic AMPs relies upon
the interaction between the peptide and the microbial
membrane to promote membrane destabilization, ultimately
leading to cell lysis (Devine and Hancock, 2002). The
relevance of the antimicrobial activity of cationic peptides
has been shown in mice, where an absence of cathelicidin
increases the susceptibility to several forms of infection,
including skin invasion by Group A Streptococcus (Nizet
et al., 2001), Citrobacter growth in the colon (Iimura et al.,
2005), and the development of Escherichia coli in urinary
tract infections (Chromek et al., 2006).
Peptides derived from the chromogranin/secretogranin
(or ‘‘granin’’) family, as well as several other neuropeptides,
including a-melanocyte-stimulating hormone, calcitonin
gene-related peptide, and neuropeptide Y, have been
reported to have antimicrobial activity in vitro (Fox
et al., 1997; Shimizu et al., 1998; Cutuli et al., 2000;
Metz-Boutigue et al., 2003b), but the significance of this
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activity in vivo remains elusive. The granin family is
distributed in secretory granules of endocrine, neuroendo-
crine, and neuronal cells (O’Connor, 1983; Taupenot et al.,
2003), but its presence is not known at sites of microbial
contact. The granin family includes chromogranin A (CHGA),
isolated from chromaffin cells of the adrenal medulla (Banks
and Helle, 1965), CgB (chromogranin B), characterized from
a rat pheochromocytoma cell line (Lee and Huttner, 1983),
and SgII (secretogranin II), originally described in the anterior
pituitary (Fischer-Colbrie et al., 1995). Granins originate as
pro-proteins stored in secretory granules with numerous
cleavage sites for endopeptidases, such as serine endopro-
teases or plasmin (Dillen et al., 1993; Eskeland et al., 1996).
Proteolytic processing of granins generates peptides that are
released into the extracellular space upon stimulation.
Chga designates the gene encoding for the protein CHGA,
which is processed at dibasic sites to give rise to several
bioactive peptides, including the 21 amino acid catestatin
(Cst). Cst was originally characterized as a catecholamine
release inhibitory peptide acting as an antagonist of the
neuronal nicotinic cholinergic receptor (Mahata et al., 1997,
1998; Taupenot et al., 2003). The amino-acid sequence
of human Cst is conserved across species (SSMKLSFRAR
AYGFRGPGPQL—human CHGA352372) (RSMRLSFRTRGYG
FRDPGLQL—mouse CHGA364384) (Mahata et al., 1997,
2004). Its calculated pI is B11.72, rendering Cst as a highly
basic peptide, and it exhibits an amphiphilic b-sheet structure
characteristic of other AMPs (Kennedy et al., 1998; Preece
et al., 2004). Recently, single nucleotide polymorphisms
have been identified in Cst and are estimated to occur in
B4% of the human population (Wen et al., 2004). These
include peptide variants Gly364Ser and Arg374Gly, which
exhibit a loss of potency, or Pro370Leu, which exhibits higher
potency as a nicotinic antagonist compared to wild-type Cst.
Interestingly, Cst was previously shown to be expressed in
peripheral mononuclear cells and exhibited antimicrobial
activity against filamentous fungi, yeast, and bacteria in vitro
(Briolat et al., 2005). However, its effectiveness against
pathogens frequently encountered by the skin was not
previously assessed.
Proteolytic processing of CHGA also results in the
generation of peptides other than Cst with AMP activity,
including prochromacin (bovine CHGA79431), chromacin I
and II (bovine CHGA173194 and bovine CHGA195221),
chromofungin (bovine CHGA4766), and vasostatin I (bovine
CHGA176). As granins are present within secretory chro-
maffin granules and are co-secreted together with catecho-
lamines during the stress response, release of such peptides
could, such as cathelicidins, provide antimicrobial activity to
counteract the suppression of cell-mediated immunity result-
ing from glucocorticoid release (Elenkov et al., 1999).
In this study, we evaluated the hypothesis that Cst exhibits
antimicrobial activity against skin pathogens and may
participate in antimicrobial defense of the skin. Our findings
demonstrate that CHGA and Cst may have a direct role in the
establishment of an innate antimicrobial barrier in the skin.
These observations support a previously undefined relationship
between the granins and cutaneous antimicrobial defense.
RESULTS
Cst is directly antimicrobial against skin pathogens
Peptides derived from CHGA were previously shown
to exhibit antimicrobial activity against microbial pathogens
in vitro, although many were not typical of those encoun-
tered during cutaneous infection (Lugardon et al., 2000;
Metz-Boutigue et al., 2003a; Briolat et al., 2005). We first
evaluated the antimicrobial activity of Cst and other peptides
derived from granins to determine which would exhibit
maximal antimicrobial activity against common skin patho-
gens. Synthetic peptides derived from CHGA, CgB, and SgII
(Table 1) were tested against relevant skin microbes,
including Gram-positive bacteria, (Staphylococcus aureus
and Group A Streptococcus (GAS)), Gram-negative bacteria
(E. coli and Pseudomonas aeruginosa), a yeast (Candida
albicans), and filamentous fungi (Aspergillus niger, Aspergil-
lus fumigatus, and Trichophyton rubrum). Of the peptides
tested, only Cst had antimicrobial activity at less than 100 mM
(Table 2). MIC (minimum inhibitory concentrations) for Cst
ranged from 5 to 50 mM. Lethal concentrations ranged from 30
to 75 mM, with lowest activity against S. aureus ATCC 25923.
Peptides based on naturally occurring human polymorphisms
of Cst that contain non-synonymous amino-acid substitutions
(Gly364Ser and Pro370Leu) (Wen et al., 2004) exhibited higher
potency against GAS and S. aureus DmprF (Table 2). Thus,
Table 1. Synthetic peptides derived from human
ChgA, ChgB, or SgII
Peptide MW
Chromogranin A
hCgA1–16 1,760
Cyclic vasostatin: hCgA17–38 2,363
hCgA39–58 2,423
hCgA57–76 2,290
hCgA79–113 3,908
hPst: hCgA273–301 3,450
hCgA324–337 1,649
hCst: hCgA352–372 2,326
hCgA375–399 2,829
hCgA411–436 2,891
Chromogranin B
hCgB420–436 1,996
hCgB498–517 2,470
hCgB555–565 1,432
hCgB568–577 1,138
hCgB635–657 2,633
Secretogranin II
hSgII131–149 2,380
Secretoneurin hSgII152–184 3,679
hSgII268–284 1,910
hChgA, human chromogranin A; hChgB, human chromogranin B; hSgII,
human secretogranin II; MW, molecular weight.
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Cst and its naturally occurring polymorphisms exhibited a
wide range of microbial targets.
To evaluate the mechanism of antimicrobial action by
Cst, membrane activity of the peptide was examined directly.
Membrane permeability was assessed over time using E. coli
strain ML-35p, which constitutively expresses a plasmid-
encoded periplasmic b-lactamase to assess disruption of the
outer membrane and a cytoplasmic b-galactosidase reporter
protein to assess disruption of the inner membrane. These
bacteria showed rapid inner membrane disruption in the
presence of 1 mg ml1 Polymyxin B (Figure 1a) or 20 mM
human Cst (Figure 1b) that was comparable to the human
cathelicidin LL-37. In E. coli, killing accompanied disruption
of the inner and outer membrane as an increase in nitrocefin
and a decrease in the red product was seen in cells treated
with Cst (data not shown). Carbonate is a critical ionic
factor found in mammalian tissues that enhances microbial
sensitivity to AMPs at physiological NaCl concentrations
(Dorschner et al., 2006). Membrane permeability to Cst was
affected by the presence of NaHCO3 in a manner similar to
cathelicidin (Figure 1a and b). Electron microscopy con-
firmed rapid disruption of E. coli by Cst (Figure 1c and f)
within 10 minutes, with visible membrane blebbing com-
pared to untreated cells (Figure 1d and g). These membrane
changes were similar to that induced by incubation with LL-37
(Figure 1e and h). Further membrane disruption of E. coli
by Cst was also observed in the presence of carbonate (data
not shown). The membrane permeating effects of Cst
were selective for bacterial membranes over mammalian
plasma membranes, as Cst induced less than 1% hemolysis of
human red blood cells at concentrations up to 100mM.
Additionally, the antimicrobial activity of wild-type Cst and
its polymorphisms was enhanced in the presence of
carbonate against both Gram-positive and Gram-negative
bacteria (Table 3).
CHGA is expressed in the skin by keratinocytes
Given that CHGA-derived peptides were antimicrobial
against a variety of skin pathogens, we sought to determine
whether CHGA was also present in the epidermis similar to
other AMPs (Koljonen et al., 2005). In normal human skin,
Cst staining was seen in the suprabasal and granular
keratinocytes within the epidermis, but not in the stratum
corneum, and to a lesser extent in the dermis (Figure 2 a
and b). The specificity of the Cst antibody was demonstrated
by incubation with pre-immune serum (data not shown) and
pre-incubation of the antibody with synthetic Cst, which
reduced the immunoreactivity to levels observed with IgG
control antibody (Figure S1). To confirm the resident skin
cells responsible for immunofluorescent staining in skin, we
performed a quantitative analysis of mRNA from whole
Table 2. Cst and naturally occurring human variants
G364S and P370L are antimicrobial against skin
pathogens
Peptide hCst Cst G364S Cst P370L
Assay MIC LC MIC LC MIC LC
Group A Streptococcus 75 75 30 30–50
Staphylococcus aureus
ATCC 25923
4100 4100 4100 4100
Staphylococcus aureus
DmprF
20 30 5–10 10 5 5
Pseudomonas aeruginosa 50 50
E. coli O29 30 30 20 20–30 10 5–10
Candida albicans
ATTC 14053
50–75 30 30–30
Aspergillus niger 20 30 20 30 10 20
Aspergillus fumigatus 20 10–20 10
Trichophyton rubrum 75 75 20 30
ATCC, American Type Culture Collection; Cst, catestatin; hCst,
human synthetic Cst; LC, lethal concentration; MIC, minimal inhibitory
concentration.
Wild-type hCst (observed inB96% of the human population) or naturally
occurring variants G364S and P370L (observed in B4% of the human
population) was tested in liquid culture for antimicrobial activity. All
numerical values are in micromolar (mM) concentration of peptide
resulting in either effective inhibition of growth of indicated microbe or
killing of microbe indicated below the designated peptide.
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Figure 1. Cst acts as an antimicrobial through membrane disruption.
Membrane permeability was determined by measuring the release of
b-galactosidase from E. coli ML-35p as detected by optical density (OD)
420 nm. (a) A 1 mg ml1 portion of polymixin B induces membrane leakage in
the presence of 25 mM NaHCO3 (open circles) but not in the absence of
NaHCO3 (closed circles). A 25 mM portion of NaHCO3 alone (open squares)
had no effect compared to untreated cells (solid squares). (b) LL-37 (4 mM,
open circles) or Cst (20mM, open squares) induces membrane leakage in the
presence of 25 mM NaHCO3 but not in the absence of NaHCO3 (solid circles
and squares). (c–h) Electron microscopy of E. coli 25922 treated for
10 minutes with (c) 50 mM Cst (original magnification  40,000), (d) untreated
(original magnification  40,000), or 10 minutes with (e) 32 mM LL-37
(original magnification  40,000). (f–h) Original magnification 15,000 of
E. coli shown in (c–e), respectively. Arrows in images (f–h) represent areas
chosen for high magnification.
www.jidonline.org 1527
KA Radek et al.
Catestatin Is an Antimicrobial Peptide Induced in Skin
human skin and cultured cells (Figure 2c). Chga transcript
was abundantly present in whole skin, and detectable in
epidermal keratinocytes at lower levels, but more abundantly
than in fibroblasts. Cultured mouse connective tissue
mast cells and human lipid-rich sebaceous cells were
also evaluated for the presence of CHGA by PCR and
immunostaining but were negative (data not shown).
High-Chga-expressing SK-N-SH cells derived from a human
neuroblastoma served as a positive control. Thus, these data
represent the first identification of CHGA in keratinocytes,
and supports the potential role for CHGA in cutaneous
immune defense.
CHGA is processed to Cst in skin
We next asked whether CHGA was processed into the
Cst peptide in skin and could thus, by virtue of its
antimicrobial activity, partially explain its presence in the
epidermis as a first line of defense against potential
skin pathogens. Further purification of skin extracts subjected
to HPLC analysis identified a small peak with mobility
in HPLC identical to synthetic Cst (Figure 3a). These
fractions also had maximal reactivity to an antibody against
Cst (Figure 3b). ESI-MS (Electrospray ionization mass
spectrometry) of this fraction defined its mass as 2,326 Da,
exactly corresponding to the predicted molecular weight
of human Cst. Based on the relative immunoreactivity
against synthetic peptide standards, the abundance of Cst
peptide in human skin was determined to be approximately
600 ng mg1 of total protein. Quantitation of Cst in normal
murine skin by immunoblot was determined to be around
20 mM within an approximate observed region of expression.
Combined, these data support the conclusion that Cst,
a presumptive AMP derived from the CHGA protein, is
endogenously present in the skin.
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Figure 2. Epidermal keratinocytes express Chga. Immunofluorescence
analysis of Cst expression in human skin. Aldehyde-fixed sections of human
skin were processed for immunohistochemistry using (a) a polyclonal
anti-human Cst or (b) rabbit IgG. (c) Relative expression of Chga mRNA in
human neuroblastoma SK-N-SH cells, whole human skin, cultured human
keratinocytes, and cultured human fibroblasts using quantitative real-time
PCR. Data represent the mean of three samples from the same tissue or cells
normalized to GAPDH and then normalized to fibroblasts.
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Figure 3. CHGA is processed into Cst in skin. (a) HPLC chromatogram of
total human skin extract. The inset shows a peak at fraction 16 corresponding
to the fraction indicated by the arrow that eluted at the same CH3CN%
(28.5%) as human Cst synthetic peptide applied identically in a following
run. Electrospray-ionization mass spectrometry identified the mass of this
peak as 2,326 Da. (b) Immunoreactivity of HPLC fractions shown in
(a) as determined by reactivity to Cst antibody. Highest immunoreactivity
is detected in fraction 16 indicated by the arrow.
Table 3. The presence of carbonate increases the
antimicrobial activity of wild-type Cst and its naturally
occurring human variants G364S and P370L
Peptide hCst Cst G364S Cst P370L
Carbonate  +  +  +
Staphylococcus aureus
ATCC 25923
4100 4100 4100 80 4100 70
Staphylococcus aureus
DmprF
30 10 20 10 15 5
E. coli ATCC 25922 50 20 30 20 40 20
ATCC, American Type Culture Collection; Cst, catestatin; hCst, human
synthetic Cst; MBC, minimal bactericidal concentration.
The effect of carbonate on the antimicrobial activity of wild-type hCst
(observed inB96% of the human population) or naturally occurring variants
G364S and P370L (observed inB4% of the human population) was tested in
liquid culture. All numerical values are in micromolar (mM) concentration of
peptide resulting in the killing of 499% of the microbe. The absence or
presence of carbonate in indicated below the designated peptide.
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Cst is upregulated in skin following injury and infection
As cutaneous injury or infection promotes an increase in
several known AMPs (Dorschner et al., 2001; Nizet et al.,
2001; Ong et al., 2002; Fluhr et al., 2006), it was of interest
to determine whether CHGA expression could also respond
to injury. Murine skin was subjected to consecutive tape
stripping and immunostained with an antibody against
the CHGA-derived neuropeptide Cst. Skin sections from
these mice exhibited expression of CHGA in the epidermis
and dermis that rapidly increased after injury (Figure 4a–d).
Cst staining was localized primarily within the suprabasal
keratinocytes, the stratum corneum of the epidermis, and in
dendritic appearing cells in the dermis. Occlusion applied
immediately after barrier disruption blocked the increase in
Cst immunoreactivity.
To determine if this increase in Cst immunostaining was
preceded by an increase in AMP gene expression, normal
skin and skin subjected to tape stripping (þ / occlusion) was
excised and assessed for the expression of both Chga and the
mouse cathelicidin, Camp, by quantitative PCR. An increase
in gene expression of both Camp (Figure 4e) and Chga (Figure
4f) was observed, but this increase was not statistically
significant, suggesting that the observed increase in protein
expression seen in Figures 4a–d may reflect release of pre-
stored peptide or amplification of a small increase in gene
expression. To determine if Chga expression in the skin may
increase in the presence of infection, normal and GAS-
infected skin was excised and assessed for the expression of
both Chga and Camp by quantitative PCR. In lesional skin,
the expression of both Camp (Figure 4g) and Chga (Figure 4h)
was significantly greater compared to normal, non-lesional
skin. These data establish that Chga is inducible by injury or
infection similarly to classical AMPs, potentially through
different mechanisms.
DISCUSSION
CHGA is widely distributed within neuronal and neuroendo-
crine tissues and is a marker for neuroendocrine tumors
(Weiler et al., 1988; Taupenot et al., 2003). The absence of
CHGA leads to hypertension in mice, a response consistent
with the role of Cst as a nicotinic cholinergic antagonist of
catecholamine release (Mahapatra et al., 2005). Neuropep-
tides and the neuroendocrine system have also been
hypothesized to be regulators of cutaneous immunity,
although direct evidence for this is lacking (Fox et al.,
1997; Ding et al., 2007). We now confirm that CHGA/Cst is
expressed by keratinocytes and is upregulated following
injury and infection. Furthermore, we show that CHGA is
processed into the peptide Cst in skin, can act as an AMP
against skin pathogens, and functions to kill bacteria in ways
similar to other known AMPs in the skin. These findings
suggest that a more direct link exists between antimicrobial
defense of the skin and the neuroendocrine system.
CHGA/Cst was detected in the epidermis by immuno-
staining and increased in both the epidermis and the dermis
following injury, suggesting that Cst could directly add to
AMP activity in the skin. Expression of Chga was confirmed in
isolated keratinocytes, but immunostaining suggested that
neural elements in the dermis also contribute to the CHGA
expression in whole skin. An additional cell of interest to
consider is the poorly understood Merkel cell. These cells are
known to express Chga, which is consequently used as a
marker for detection of Merkel cell tumors (Koljonen et al.,
2005). Our observation of CHGA function in skin also
provides a new hypothesis for an immunological role for the
Merkel cell. Thus, we speculate that the keratinocyte may act
as a reservoir for CHGA storage and are induced to release
CHGA into the extracellular environment following tissue
damage or infection, whereas the Merkel cell may serve to
impart a constitutive cutaneous immune surveillance.
In antimicrobial assays, human Cst (CHGA352–372)
exhibited activity against multiple organisms and behaved
similarly in vitro to other AMPs. For example, some AMPs kill
optimally when carbonate is present, mimicking ionic
conditions in vivo (Dorschner et al., 2006). Cst behaved
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Figure 4. CHGA is upregulated following barrier disruption and infection.
Immunofluorescence analysis of Cst expression in injured mouse skin.
Acetone-fixed sections of mouse skin subjected to consecutive tape-stripping
þ / occlusion were processed for immunohistochemistry using a polyclonal
anti-rodent Cst antibody. Cst staining is shown at (a) baseline, (b) 3 hours post-
tape stripping and (c) 3 hours post-tape stripping with occlusion. (d) Rabbit
IgG as a negative control. Bar¼40 mm. The expression of Camp (e) or Chga
(f) was analyzed by quantitative PCR in normal, non-injured skin (control),
or in skin 3 hours after tape stripping þ / occlusion. The expression of
Camp (g) or Chga (h) was analyzed by quantitative PCR in normal,
non-lesional skin from uninfected mice (control), or in lesional skin
24 hours after infection with GAS. Data are shown as the mean±SEM
by Student’s t-test, n¼3–4 per group, repeated twice. *Po0.05.
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similarly, as Gram-negative and Gram-positive bacteria
become more susceptible to Cst in the presence of carbonate.
In addition, enhanced antimicrobial activity of Cst was
observed against the mutant S. aureus DmprF. The membrane
of this mutant lacks lysylphosphatidylglycerol, which results
in a more negative charge of the membrane surface (Peschel
et al., 2001; Oku et al., 2004). As a consequence of this,
S. aureus DmprF has an increased affinity for cationic
peptides and displays a greater susceptibility to AMPs that
require ionic interactions with the membrane (Peschel et al.,
2001; Ruzin et al., 2003; Nishi et al., 2004). Thus, the current
results suggest that Cst exerts its effect by a mechanism
requiring electrostatic interaction with the membrane. Support
for a membrane-active model of activity can also be derived
from the increase in potency observed in the Cst variants.
Homology modeling suggests that both substitutions distort the
peptide backbone in the middle loop by 0.36 A˚ or 0.59 A˚
(Gly364Ser or Pro370Leu, respectively; Wen et al., 2004). This
shift in the middle loop can increase the capacity of the peptide
to interact with the membrane, explaining the increased
activity of mutants compared to wild-type Cst. These observa-
tions of antimicrobial activity for Cst against skin pathogens are
supported by prior in vitro analysis of its antimicrobial activity
against other microorganisms (Briolat et al., 2005).
Whereas the minimum effective antimicrobial concentra-
tions of Cst was 5mM or greater, the typical circulating plasma
concentrations of CHGA (Takiyyuddin et al., 1990) and Cst
(O’Connor et al., 2002) are in the nanomolar range. As the
sequence of Cst is conserved across species, particularly
between mouse and human, it is likely that the AMP activity
of mouse Cst is comparable to human Cst. In these skin
studies, the amount of Cst in murine epidermis was
determined to be approximately 20 mM in its approximate
observed area of expression, suggesting that there is sufficient
amount of Cst locally to contribute to immune defense.
However, two main factors make it difficult to determine the
precise concentration of an active AMP within a designated
tissue. First, the amount of the specific active proteolytic
fragment, such as Cst, may be overestimated as the antibody
recognizes many forms of CHGA containing the Cst
sequence. Second, volume of the compartment in which it
is distributed, and thus the denominator necessary to
calculate the concentration of peptide, is difficult to
accurately measure. Owing to these difficulties, it is not
possible to definitively conclude that the local concentration
of Cst exceeds that necessary to directly kill bacteria.
The abundant increase in CHGA/Cst following injury and
infection supports its role to directly act as an AMP after
injury. The abundance of mRNA of both Chga and Camp was
increased following infection, but not significantly increased
following barrier disruption. However, an increase in protein
expression following tape stripping was seen and this was
blocked by Latex occlusion. Cst is stored in secretory
granules of the adrenal medulla, whereas cutaneous AMPs,
such as cathelicidin, are partially stored in lamellar bodies
and Golgi apparatus within keratinocytes (Eskeland et al.,
1996; Braff et al., 2005). Both CHGA and cathelicidin are
processed and then released from these secretory granules
during periods of stress, for example, during infection and/or
injury. Furthermore, the artificial restoration of the epidermal
barrier using Latex occlusion immediately following barrier
disruption by tape stripping inhibited the increase in Cst,
indicating that barrier integrity regulates the release of
Cst. Thus, injury may induce sufficient amounts of pre-stored
Cst to be released into the microenvironment, whereas in the
presence of infection, the increase in gene expression may
provide a secondary defense mechanism to ensure that
sufficient AMP activity by Cst is made available following
depletion of pre-stored reservoirs. After injury, Cst would be
available to provide an immediate defense against microbial
pathogens, making the antibacterial concentrations observed
in vitro physiologically relevant. However, it clearly appears
that the abundance of Cst in skin is relatively low and its
antimicrobial potency is not as great as other cutaneous AMPs.
Therefore, it remains to be determined if the expression of Cst
in skin provides a considerable increase in cutaneous protec-
tion related to other innate immune defense mechanisms.
CHGA has been reported to regulate the endothelial
barrier following inflammation to protect against vascular
leakage caused by tumor necrosis factor-a (Ferrero et al.,
2004). In the skin, expression of CHGA may play a similar
role during pathological states, such as infection, when tumor
necrosis factor-a levels are elevated. Other studies have
demonstrated that stress results in the mobilization of
immune cells (Viswanathan et al., 2005; Atanackovic et al.,
2006) and CHGA is known to be expressed in response to
stress (Jiang et al., 2001). Furthermore, recent observations
have identified direct links between glucocorticoid produc-
tion and innate immune function of the skin barrier. (Aberg K,
Gallo RL, Mauro TM, Feingold KR, Elias PM. Society for
Investigative Dermatology, Meeting Abstract, 2006). Thus,
further analysis is warranted to determine whether Cst may
function in skin in a way other than acting as a direct AMP.
In conclusion, the current findings suggest that granins and
their fragments contribute to host innate defenses against
microbes, with Cst possibly acting directly as an AMP. The
observation of expression of a secreted neuroendocrine
molecule by keratinocytes, its induction within the epidermis
following injury, its dependence upon barrier integrity, and
its ability to act as both a natural antibiotic and a
neuropeptide provides new insight into the integral commu-
nication between the neural and cutaneous immune system.
These results indicate that CHGA/Cst may be a key factor of
the local innate defense of skin. Further investigation is essen-
tial to determine how CHGA/Cst participates in cutaneous
immunity. Potentially, the stress response associated with the
adaptive fight-or-flight state could influence the cutaneous
immune system through CHGA to alter the risk of infection.
Ultimately, these previously unidentified observations indi-
cate that the skin is a functioning neuroendocrine tissue that
can modulate inherent antimicrobial activity.
MATERIALS AND METHODS
Peptides
Peptides were from Imgenex (San Diego, CA) and 95% purity
confirmed by mass spectrometry.
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Microorganisms
S. aureus Rosenbach ATCC 25923 (ATCC, American Type Culture
Collection, Manassas, VA), S. aureus DmprF, the enteroinvasive
E. coli O29, E. coli ATCC 25922, P. aeruginosa, and GAS were used.
Yeast used was C. albicans ATCC 14053. Fungi used were clinical
isolates of A. niger, A. fumigatus, and T. rubrum.
Bacteria were grown at 37 1C in tryptic soy broth (TSB; Sigma,
St Louis, MO) to stationary phase and a 10 suspension at 1–3 106
colony-forming units (CFU) ml1 prepared in 1 mM NaPB (sodium
phosphate buffer), pH 7. Yeast was grown at 37 1C in a modified
Dixon made of 4% malt extract (Fluka Biochemika, Steinheim,
Germany), 0.6% Bacto Peptone (Becton Dickinson, Sparks, MD),
1% glucose (Sigma-Aldrich Co., St Louis, MO) and 1% Tween 80
(Sigma-Aldrich Co.) and a 10 suspension at 3–6 105 CFU ml1
was prepared in 1 mM NaPB. Fungi were routinely cultured on potato
dextrose agar (Becton Dickinson, Sparks, MD) plates for 5–10 days at
30 1C. Conidia were collected from agar, filtered, and titrated to a
concentration of 106 conidia per ml in 1 mM NaPB.
In vitro antimicrobial activity assays
Microorganisms were grown in 100 ml in sterile 96-well microtiter
plates (Corning Inc., Corning, NY). The assay mixture contained
1 mM sodium phosphate buffer, 10 ml of a 10 suspension of each
microorganism, 20% of culture media (TSB for bacteria, modified
Dixon media for yeast, or potato dextrose agar media for fungi as
described above), and 10 ml of a 10 solution of each synthetic
peptide (final concentrations ranging from 5 to 100mM). For fungi or
yeast, the assay also contained 16 mg ml1 chloramphenicol per
well. The plates were incubated at 30 1C for yeast and fungi or 37 1C
for bacteria, and the growth was determined by measure of A600 over
time with a Spectra max PLUS 384 (Molecular Devices, Sunnyvale,
CA) microplate reader. In each experiment, the blank mean A600
value from mock inoculations was subtracted from each well A600
measurement to calculate the mean and SD.
The MIC was defined as the lowest peptide concentration that
showed at least 95% inhibition of growth at the end of the
experiment (after 1 day for bacteria, 2 days for yeast or fungi). In
the case of some fungi, the MIC was determined as the lowest
peptide concentration that prevented visual growth. Aliquots of each
pathogen–peptide combination were also plated in agar to determine
the lethal concentration defined as the lowest peptide concentration
enabling o1% of growth recovered after treatment.
Hemolysis assay
Hemolytic activity was determined from human whole blood,
freshly obtained and washed and resuspended in phosphate-buffered
saline (PBS) with peptides at different concentrations. Blood was
obtained following informed consent and as approved by the UCSD
Human Research Protection Program protocol #031263. Samples
were incubated at 371C for 2 hours and hemolysis determined by
measurement of absorbance at 410 and 578 nm. The hemolytic
activity of each peptide was expressed as the percentage of total
hemoglobin released compared with that released by incubation
with 0.1% Triton X-100 as a positive control.
Membrane permeability
E. coli strain ML-35p was used to measure inner and outer
membrane permeability. This strain constitutively expresses a
plasmid-encoded periplasmic b-lactamase and cytoplasmic
b-galactosidase, but lacks lactose permease. After overnight incubation
at 371C in TSB, cultures were re-inoculated in buffer A (1 mM
NaH2PO4, 20% TSB) or buffer B (1 mM NaH2PO4, 20% TSB and
25 mM NaHCO3) for 3 hours. The subculture was then adjusted to
2.5–5 107 CFU ml1 (A600¼ 0.03) in buffer A or B.
To test permeabilization of the inner membrane, formation of
ONP (o-nitrophenol) as the hydrolytic product of b-galactosidase on
the colorless substrate ONPG (o-nitrophenyl-b-D-galactosidase) was
determined by detecting in increase in absorbance at 420 nm (A420).
To study permeabilization of the outer membrane, we followed a
decrease in A390 due to the substrate nitrocefin and an increase in
A486 due to the red product. The assay mixture contained 43 ml of
bacteria from stock cultured in buffer A or B, with final concentra-
tions of 4mM LL-37, 20 mM Cst, 0.3 mg ml1 ONPG, or 25 mg ml1
nitrocefin. The concentrations of LL-37 and Cst used in this assay
was determined as the optimal concentration which resulted in little
to no toxicity while retaining maximal activity with this strain of
E. coli. To observe bacterial growth, the A600 was also monitored.
For the assay, samples were incubated at 37 1C in sterile 96-well
microtiter plates (Corning Inc.) and the kinetics of b-galactosidase or
b-lactamase activity calculated by the measurement of the A420
or A390/486, respectively. Absorbance was determined using a
SpectraMax PLUS 384 device (Molecular Devices). As a positive
control, bacteria were permeabilized with 1mg ml1 polymyxin B
(Calbiochem, La Jolla, CA) and 1% Triton X-100 in buffer A or B.
Electron microscopy
Electron microscopy was performed on E. coli (ATCC 25922) grown
to log phase in 20% TSB, 1 mM NaH2PO4. LL-37 (32 mM, positive
control), Cst (50 mM), or an equal volume of water (negative control)
was added to 108 bacteria and cultured for 10 minutes. Bacteria
were pelleted at 1,000 g for 2 minutes at 4 1C, immersed in 4 1C 5%
phosphate-buffered glutaraldehyde, pH 7.8, rinsed in cold phos-
phate buffer, post-fixed in 4% phosphate-buffered osmic acid for
2 hours, dehydrated in acetone, and embedded. Samples were
processed for electron microscopy on a Zeiss EM transmission
electron microscope.
Immunohistochemistry and three-dimensional imaging on
human skin
Immunohistochemistry was performed on healthy human skin that
was immediately embedded in OCT (optimal cutting temperature)
compound (Sakura Finetechnical Co., Tokyo, Japan). Sections
(10 mm) were fixed in 10% buffered formalin and then washed with
PBS. Sections were blocked with 2% goat serum/3% BSA (Sigma) in
PBS and incubated with a polyclonal rabbit anti-Cst antibody
(1:1,000 in PBS containing 3% BSA). As a negative control, normal
rabbit IgG was diluted with PBS at the same concentration as
primary antibody. Slides were washed in PBS and then incubated
with goat anti-rabbit IgG/Tetra Methyl Rhodamine Isothiocyanate
(TRITC)-conjugated IgG/(Sigma, work solution 1:200 in PBS
containing 3% BSA).
Images were captured on a DeltaVision deconvolution micro-
scopy system (Applied Precision, Issaquah, WA) operated by
SoftWoRx software (Applied Precision) on a Silicon Graphics O2
workstation using  60 (NA 1.4) or  100 (NA 1.4) oil immersion
objectives. The fluorescent data sets were deconvoluted and
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analyzed by DeltaVision SoftWoRx proGrams (Applied Precision) on
a Silicon Graphics Octane workstation to generate optical sections
or three-dimensional images of the data sets.
Cell culture
Normal human keratinocytes isolated from foreskin were cultured
in EpiLife medium (serum-free keratinocyte medium; Cascade
Biologics, Portland, OR) supplemented with 0.06 mM calcium,
EDGS (EpiLife defined growth supplement), and penicillin/
streptomycin. Fibroblasts ATS F12 were cultured in DMEM—high
glucose, no potassium azida medium (Cambrex, Walkersville,
MD) supplemented with 10% bovine serum, 1% L-glutamine,
1% MEM (minimum essential medium)—non-essential amino acids
and 1% penicillin/streptomycin (all purchased from Invitrogen
Corporation, Carlsbad, CA). Propagation of human neuroblastoma
SK-N-SH cells was performed according to the provider instructions
(ATCC).
Quantitative real-time PCR for human skin, keratinocytes, and
fibroblasts
Skin was biopsied and homogenized directly in Trizol reagent. RNA
from skin was extracted per the manufacturer’s instructions. Total
RNA from cells was isolated using Qiagen RNeasy Mini Kit (Qiagen,
Valencia, CA). Reverse transcription of RNA isolated from skin tissue
or cells into cDNA was achieved using Retroscript kit (Ambion,
Austin, TX), following manufacturer’s instructions.
Quantitative real-time PCR was performed using an Applied
Biosystems 7000 Sequence Detection System (Foster City, CA). For
human Chga, primers were designed for the target gene human Chga
(hChga) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
as an endogenous control. The sequences of the hChga primers were
forward TGTAGTGCTGAACCCCCACC, reverse CTCTCGCCTTTC
CGGATCT (product size 57 bp). These primers bind in the base 966
for the forward and 1,004 for the reverse of the cDNA NM_001275.
The sequences of the GAPDH primers were forward CTTAGCA
CCCCTGGCCAAG, reverse TGGTCATGAGTCCTTCCACG (product
size 62 bp). Five microliters of cDNA was added to 12.5 ml SYBR
Green PCR Master Mix (Applied Biosystems), 0.25ml of each 20 mM
primer, and 7ml of RNase/DNase-free H2O per reaction. Thermal
profile is as follows: 50 1C 2 minutes, 95 1C 10 minutes, 40 (94 1C
15 seconds, 60 1C 1 minute). Results were analyzed using the
comparative Ct method (User Bulletin no. 2, Applied Biosystems).
HPLC purification and immunoblot of human skin extracts
Human skin biopsies obtained following informed consent and as
approved by the University of California, San Diego Human
Research Protection Program, protocol no. 031263, were extracted
and fractionated by HPLC as described below.
Peptide separation was performed using an AKTA purification
system (Amersham Pharmacia Biotech, Pistacaway, NJ) on a
Sephasil peptide C18 column (12 mm, ST 4.6/250) (Amersham
Pharmacia Biotech). HPLC was equilibrated in 0.1% trifluoroacetic
acid at a flow rate of 0.5 ml minute1 and eluted using a gradient of
0–100% acetonitrile, and monitored at 214, 230, and 280 nm. All
collected fractions (1 ml) were lyophilized and then resuspended in
15ml of sterile double-distilled H2O (Life Technologies, Carlsbad, CA).
For quantification of Cst, fractions were diluted in TBST
(Tris-buffered saline-1% Tween), pH 7.0, transferred to a
polyvinylidene fluoride membrane, then incubated with anti-rodent
Cst antibody (1:1,000) or anti-human Cst antibody (1:500) in
TBST/5% milk/5%BSA overnight at 4 1C. The membrane was washed
and incubated with horseradish peroxidase-conjugated goat
anti-rabbit antibody for 1 hour at room temperature and developed
with ECL reagent (Amersham Pharmacia Biotech). The relative
immunoreactivity was determined by ChemiImager version 5.5
software.
Animals
For all experiments, age-matched (8–10 weeks) and sex-
matched adult littermates were used. All procedures performed
in accordance with the Veterans Affairs San Diego and Veterans
Affairs San Francisco Healthcare System subcommittee on animal
studies.
Barrier disruption
Epidermal barrier disruption was induced by sequential cellophane
tape stripping on the flanks of female Skh-1 mice as described
previously (Wood et al., 1992). In some experiments, animals
were occluded with a tightly fitted water vapor-impermeable
latex membrane to artificially restore barrier function. Briefly, skin
biopsies were taken from treated animals at baseline and 30 minutes,
1 hours, and 3 hours after barrier disruption and were immediately
embedded in OCT compound and snap-frozen in liquid nitrogen
(Sakura Finetechnical Co.).
Immunohistochemistry on mouse skin following barrier
disruption
Tissue sections (10 mm) were fixed in 100% acetone and rinsed in
PBS. Sections were incubated for 30 minutes in blocking buffer (4%
BSA, 0.5% cold water fish gelatin in PBS) and incubated over night
at 4 1C with a 1:3,000 dilution of primary antibody in blocking
buffer. Sections were washed and incubated for 40 minutes at room
temperature with an Alexa Fluor 488-conjugated goat anti-rabbit
secondary antibody. Tissue sections were counterstained with
propidium iodide and visualized on a Leica TCS-SP confocal
microscope. Photos were taken at  40 magnification.
GAS infection
GAS infection was performed as described previously (Betschel
et al., 1998). Hair was removed from the back of anesthetized male
129/SvJ mice by plucking. Skin was then injected with 50 ml of a
mid-logarithmic growth phase (A600¼ 0.8, 4.8 108 CFU ml1) of
GAS NZ131 conjugated with 50ml of sterile Cytodex beads. Skin
from noninfected mice was used as a control. Normal or infected
skin was excised using a 8 mm biopsy punch.
Quantitative real-time PCR for normal, tape-stripped, or
GAS-infected mouse skin
Normal, tape-stripped (þ / occlusion), or lesional skin was excised
and RNA isolated as described above. Quantitative PCR for mouse
cathelicidin gene (CRAMP) was analyzed as described above using a
FAM-CAGAGGATTGTGACTTCA-MGB probe with primers 50-CTT
CACCAGCCCGTCCTTC-30 and 50-CCAGGACHGACACAGCAG
TCA-30 and normalized to GAPDH using primers described above.
A predeveloped Taqman assay probe (ABI, Foster City, CA) was used
for the analysis of mouse Chga.
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Measurement of Cst in murine epidermis
Normal murine skin was excised, minced, and incubated in dispase
(Boehringer-Manheim, Manheim, Germany) at a concentration of
5 mg ml1 in 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid) buffer overnight at 4 1C. Epidermis was removed,
homogenized in 1 RIPA (radioimmunoprecipitation assay)
buffer, and centrifuged at 1,000 g for 15 minutes at 4 1C. Epidermal
supernatant was then blotted onto a polyvinylidene fluoride
membrane along with Cst standards. The membrane was blocked
and incubated with anti-Cst antibody (1:1,000) at room temperature.
Blot was then incubated with goat anti-rabbit horseradish peroxidase
and developed with ECL (enhanced chemoluminescence) reagent
(Perkin-Elmer, Boston, MA). Epidermal extract reactivity was
determined by comparing to reactivity of known concentrations of
Cst ranging from 500 nM to 100 mM. To estimate the concentration of
peptide in the epidermis, the calculated molar mass of peptide
reacting to anti-Cst antibody was divided by an estimated volume of
tissue identified to contain Cst by immunohistochemistry. For the
area of skin excised, this volume was 18 mm3.
Statistical analysis
Data were analyzed using GraphPad Prism, version 2.1. (GraphPad
Software Inc., San Diego, CA). The means and SD were calculated
for each data set. Data were analyzed by an unpaired Student’s t-test.
P-values o0.05 were considered significant.
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